Clinical Trials Logo

Clinical Trial Summary

The aim of the THEIA study is to determine if Alteplase administrated within 4.5 hours improve visual deficit due to acute CRAO with a good safety profile.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03197194
Study type Interventional
Source Nantes University Hospital
Contact
Status Completed
Phase Phase 3
Start date June 8, 2018
Completion date January 16, 2024

See also
  Status Clinical Trial Phase
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Recruiting NCT04526951 - TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS) Phase 3
Recruiting NCT04965038 - Early Reperfusion Therapy With Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion Phase 3
Not yet recruiting NCT06178055 - A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arthritic Central Retinal Artery Occlusion (CRAO) Phase 2
Recruiting NCT01348633 - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye N/A
Recruiting NCT05562284 - Safety and Efficacy After Selective Intra-arterial Thrombolysis for Central Retinal Artery Occlusion N/A
Completed NCT05739487 - Changes of Visual Field Defects After IAT for CRAO
Completed NCT03049514 - Study of Arterial Recanalization of the Central Retinal Artery Occlusions
Recruiting NCT00802698 - The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform Phase 1/Phase 2